糖尿病黄斑浮腫眼におけるルセンティス（ラニビズマブ）硝子体内投与後の酸素消費量の変化

基本情報

NCT ID

NCT02329132

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

30

治験依頼者名

Kagawa University

概要

Recent reports suggest that anti-VEGF agents (ranibizumab) may suppress the progression of retinal nonperfusion area. This protective effect would cause the increase of the oxygen consumption in the diabetic retina. We expect that the current study using the retinal oximetry would show the protective effects of ranibizumab on the hypoxia in the diabetic retina. This study is designed to analyze the effects of ranibizumab (Lucentis) to the retinal oxygen saturation or consumption in eyes with diabetic macular edema.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)